ATG2A

Across TCGA pan-cancer cohorts, ATG2A Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated ATG2A data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher ATG2A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATG2A expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

COAD, SARC, and PRAD are the cancer types where ATG2A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	0.353	0.802	<.001	17	view →
SARC	DFS	Median	All	0.069	0.632	<.001	12	view →
PRAD	DFS	Median	All	0.096	0.776	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	III,IV	0.123	0.654	.004	6	view →
KICH	DFS	Median	All	0.121	0.867	.023	5	view →
ESCA	OS	Median	All	0.299	0.564	.037	4	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
LUSC	OS	Median	All	0.305	0.728	.040	3	view →
STAD	DFS	Median	All	0.767	0.380	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

ATG2A–COAD (DFS)

Open the COAD breakdown →